skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

22 Total results for product and free and sample content found

Medtech Insight

MTI Top 100: Leading Medtechs See Steady Organic Growth In A Market On The Cusp Of Change

By Ashley Yeo 11 Dec 2019

Analysis

The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.

In Vivo

Medtechs Enter The Decade of Digital, Consumers and Wellness

By Ashley Yeo 11 Dec 2019

Analysis

For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

In Vivo

Brexit To And Fro Continues Into Fresh Decade

By Ian Schofield 06 Dec 2019

Analysis

Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.

Topic Business Strategies Policy and regulation

Scrip

Pharma Finds Its Way in AI

By Leah Samuel 06 Dec 2019

Analysis

Early adopters of artificial intelligence are discovering how best to use it. Some of them are sharing lessons they have learned. 

Scrip

Novartis Sees Reimbursement Advantage For PCSK9 Launch

By Jessica Merrill 28 Nov 2019

Analysis

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

Topic Business Strategies Deal trends Reimbursement

In Vivo

From US To EU: Young Biotechs Going It Alone

By Jo Shorthouse 28 Nov 2019

Analysis

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

In Vivo

MHealth And Research In Oncology

By Niharika Dandamudi 20 Nov 2019

Analysis

The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices.”

Topic Digital Health Personalized Medicine

Generics Bulletin

Amneal Starts Seeking International Partners

By Aidan Fry 20 Nov 2019

Analysis

In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.

Topic Business strategies

Scrip

Gene and Cell Therapies In Asia: Can China Deliver Despite Murky Regulations?

By Brian Yang 20 Nov 2019

Analysis

The first country ever to approve a gene therapy, China has been lagging in the area since due to a lack of clear regulatory pathways and insufficient financial incentives. Now a new crop of developers are aiming to revitalize ambitions and make the country a major power for promising novel treatments for rare neurodegenerative conditions, retinal dystrophy, HIV and cancer.

Topic Policy and regulation

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: